Clinical Trial

Longitudinal Study of Retinal Function in Eyes Treated for Diabetic Macular Edema With Anti-VEGF Agents

Study acronym: AS
Not Yet Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
A considerable hurdle to the development of novel, more effective therapies for diabetic retinal disease is the limited number of primary endpoints available for use in regulatory trials. Current endpoints necessitate long trial durations and a greater number of participants to show efficacy. Thus, a better understanding of the structural and functional changes in the retina occurring in people with diabetes is essential for developing primary endpoints and validating surrogate and clinical endpoints.
Trial Details
NCT Number NCT07567833
Lead Sponsor Jaeb Center for Health Research
Collaborators: National Eye Institute (NEI)
Conditions Diabetic Retinal Disease
Enrollment 100 participants
Start Date 2026-05-01
Primary Completion 2027-12 (estimated)
Study Completion 2033-05 (estimated)
Updated on ClinicalTrials.gov 2026-05-05